Genelabs Technologies Inc. (NASDAQ:GNLB) announcedWednesday that its anti-cancer drug GL331 has begun Phase Iclinical trials at The University of Texas M.D. Anderson CancerCenter in Houston.
This chemotherapy agent is designed to overcome multipledrug resistance, and is the first such compound to enter clinicaltrials, the company said.
GL331 was developed by Genelabs of Redwood City, Calif., incollaboration with the University of North Carolina and theNational Cancer Institute. It has been shown to overcomemultiple drug resistance in animal and other laboratorystudies.
(c) 1997 American Health Consultants. All rights reserved.